Scholarlink

Background <p>The Hypertension Treatment in Nigeria Program was implemented across 60 primary healthcare centers (PHCs) in Nigeria to improve hypertension treatment and control using the World Health Organization’s HEARTS package. This study reports the program’s implementation outcomes.</p> Methods <p>The Hypertension Treatment in Nigeria Program used a type 2 hybrid interrupted time series design, and data were collected from January 2020 to December 2023. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework guided the evaluation, focusing on key metrics such as patients’ and clinics’ characteristics, prescription rate of fixed dose combination (FDC) drugs, medication availability, and retention.</p> Results <p>Among 21,922 patients recruited (mean [SD] age = 49 [12], 68.1% female) from 60 primary healthcare centers (78.3% rural). Prescription of FDC increased from 16.3 (95% CI: 4.8%—27.8%) to 65.2% (95% CI: 64.0%—66.3%). The program distributed 336,116 30-day medication supplies, and nearly all (95%) PHCs had at least one 30-day supply of any BP-lowering medication in stock after the drug revolving fund implemented. The patient retention rate at 6&#xa0;months increased between the pre-implementation to implementation periods from 59.9% to 63.1%.</p> Conclusions <p>The Hypertension Treatment in Nigeria Program successfully integrated hypertension services into Nigerian primary healthcare centers. Future efforts should focus on sustaining and scaling up the program’s success.</p> Trial Registration <p>The trial has been registered at <a href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</a> under NCT04158154.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Implementation outcomes from the Hypertension Treatment in Nigeria program: results from a type 2 hybrid interrupted time series trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Jiancheng Ye,
  • Lisa R. Hirschhorn,
  • Abigail S. Baldridge,
  • Erica L. Jamro,
  • Ikechukwu A. Orji,
  • Gabriel L. Shedul,
  • Nanna R. Ripiye,
  • Tunde M. Ojo,
  • Helen Eze,
  • Grace J. Shedul,
  • Eugenia N. Ugwuneji,
  • Rosemary C. B. Okoli,
  • Boni M. Ale,
  • Samuel Osagie,
  • Olutobi A. Sanuade,
  • Guhan Iyer,
  • Namratha R. Kandula,
  • Dike B. Ojji,
  • Mark D. Huffman

摘要

Background

The Hypertension Treatment in Nigeria Program was implemented across 60 primary healthcare centers (PHCs) in Nigeria to improve hypertension treatment and control using the World Health Organization’s HEARTS package. This study reports the program’s implementation outcomes.

Methods

The Hypertension Treatment in Nigeria Program used a type 2 hybrid interrupted time series design, and data were collected from January 2020 to December 2023. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework guided the evaluation, focusing on key metrics such as patients’ and clinics’ characteristics, prescription rate of fixed dose combination (FDC) drugs, medication availability, and retention.

Results

Among 21,922 patients recruited (mean [SD] age = 49 [12], 68.1% female) from 60 primary healthcare centers (78.3% rural). Prescription of FDC increased from 16.3 (95% CI: 4.8%—27.8%) to 65.2% (95% CI: 64.0%—66.3%). The program distributed 336,116 30-day medication supplies, and nearly all (95%) PHCs had at least one 30-day supply of any BP-lowering medication in stock after the drug revolving fund implemented. The patient retention rate at 6 months increased between the pre-implementation to implementation periods from 59.9% to 63.1%.

Conclusions

The Hypertension Treatment in Nigeria Program successfully integrated hypertension services into Nigerian primary healthcare centers. Future efforts should focus on sustaining and scaling up the program’s success.

Trial Registration

The trial has been registered at www.clinicaltrials.gov under NCT04158154.